Table 1.
The clinicopathological characteristics of the included patients.
| Characteristics | Total (n=42) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| HR (95%CI) | P value | HR (95%CI) | P value | |||
| Age (years), (median [IQR]) | 62.00 (12.00) | 0.943 (0.915–0.972) | 0.000* | 0.972 (0.936–1.008) | 0.129 | |
| Gender, n (%) | 0.534 (0.257–1.112) | 0.094 | ||||
| Male | 31(73.814%) | |||||
| Female | 11(26.19%) | |||||
| ECOG PS, n (%) | 0.658 (0.353–1.223) | 0.186 | ||||
| 0 | 20 (47.628%) | |||||
| 1 +–2 | 22 (52.3852%) | |||||
| Treatment regimen, n (%) | 0.797 (0.359–1.769) | 0.576 | ||||
| Anti-PD-1/PD-L1 | 29 (69.04%) | |||||
| Anti-PD-1 + anti-CTLA-4 | 13 (30.95%) | |||||
| Treatment cycle, n (%) | 1.229 (0.820–1.844) | 0.318 | ||||
| Two cycles | 33 (78.57%) | |||||
| Three cycles | 9 (21.43%) | |||||
| Lauren type, n (%) | ||||||
| Intestinal | 19 (45.23%) | [reference] | [reference] | |||
| Diffuse | 11 (26.19%) | 3.629 (1.553–8.478) | 0.003* | 3.155 (1.203–8.275) | 0.020* | |
| Mixed | 7 (16.677%) | 2.370 (0.883–6.362) | 0.087 | 1.924 (0.668–5.540) | 0.225 | |
| No testing | 5 (11.9012%) | 0.570 (0.161–2.026) | 0.385 | 0.409 (0.087–1.933) | 0.259 | |
| Differentiation, n (%) | 1.157 (0.578–2.317) | 0.680 | ||||
| Moderate | 17 (40.481%) | |||||
| Poor | 25 (59.5260%) | |||||
| PD-L1, n (%) | ||||||
| Negative | 12 (28.579%) | [reference] | ||||
| Positive | 17 (40.48%) | 0.520 (0.228–1.185) | 0.119 | |||
| No testing | 13 (30.951%) | 0.604 (0.256–1.427) | 0.250 | |||
| MMR, n (%) | ||||||
| pMMR | 33 (78.579%) | [reference] | ||||
| dMMR | 4 (9.5210%) | 0.296 (0.069–1.279) | 0.103 | |||
| No testing | 5 (11.902%) | 2.282 (0.836–6.227) | 0.107 | |||
| EBV, n (%) | ||||||
| Negative | 23 (54.765%) | [reference] | ||||
| Positive | 12 (28.579%) | 0.875 (0.361–2.122) | 0.768 | |||
| No testing | 7 (16.677%) | 2.103 (0.834–5.310) | 0.115 | |||
| peritoneal metastasis, n (%) | 0.513 (0.254–1.036) | 0.063 | 1.187 (0.469–3.007) | 0.717 | ||
| Present | 20 (47.62%) | |||||
| Absent | 22 (52.38%) | |||||
| Hepatic metastasis, n (%) | 1.263 (0.616–2.589) | 0.524 | ||||
| Present | 15 (35.71%) | |||||
| Absent | 27 (64.29%) | |||||
| Number of metastatic sites, n (%) | ||||||
| 1 | 7 (16.67%) | [reference] | [reference] | |||
| 2 | 29 (69.05%) | 1.640 (0.566–4.755) | 0.362 | 2.022 (0.546–7.481) | 0.292 | |
| 3+ | 6 (14.29%) | 3.431 (0.955–12.321) | 0.059 | 4.881 (0.884–26.939) | 0.069 | |
| ΔVintra_ZV, (median [IQR]) | -0.07 (0.54) | 2.320 (1.478 – 3.641) | 0.000* | 1.911 (1.163–3.142) | 0.011* | |
| postVperi_Sphericity, mean (SD) | 0.00 (1.00) | 0.601 (0.410 – 0.882) | 0.009* | 0.690 (0.421–1.132) | 0.142 | |
IQR, interquartile ranges; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status score; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; MMR, mismatch repair; dMMR, mismatch repair deficiency; pMMR, mismatch repair proficiency; EBV, Epstein–Barr virus.